Cefpodoxime


Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the US, according to the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins are no longer necessary for continued treatment.
Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.
It was patented in 1980 and approved for medical use in 1989.

Spectrum of bacterial susceptibility and resistance

Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.
markets cefpodoxime proxetil under the trade name Simplicef for veterinary use. The dose range in dogs is 5-10 mg/kg body weight, administered orally, once a day. Finecure, India markets the products under trade name Cefpo.
Vantin in suspension or tablet form.
Toraxim
Trucef
Orelox
MAPDOX-CV: Cefpodoxime and Clavulanic acid combination
MONOTAX O / MONOTAX CV
POSTPOD-50